2023 iNFo Fair

Christi is a family nurse practitioner who has worked with the Surgical Neurology Branch at the National Institutes of Health since 2012. She works with patients with NF2 and other neurosurgical disorders in both inpatient and outpatient settings. She values her role as an associate investigator on the NF2 study and enjoys working with the PI, other investigators, and the multi-disciplinary care team to learn more about NF2 and contribute towards efforts to progress research and improve care.  

Dr. Ethan Lester is a clinical psychologist at Massachusetts General Hospital, an Assistant Professor at Harvard Medical School, and an affiliated researcher with the Center for Health Outcomes and Interdisciplinary Research. Dr. Lester specializes in behavioral medicine and mental health care for people with neurological illnesses and conducts individual psychotherapy/counseling visits with patients at the hospital. Specific to NF, Dr. Lester was the lead clinician on the Department of Defense Funded Clinical Trial at MGH for adults with NF1, NF2, and Schwannomatosis and is also the creator of the web-platform www.NF-Web.org (click to check it out), funded in part by NF Midwest.  

Dr. Prada finds it an honor to work with children, adults, and families with genetic diseases. His clinical work focuses on improving health for individuals with rare diseases by developing individualized and integrated care across specialties to promote their wellbeing. For 6 years, he co-led the RASopathies program at Cincinnati Children’s Hospital to develop a care-based model on genetic pathways. He has conducted randomized clinical trials of lysosomal storage disorders, neurofibromatosis type 1, RASopathies, mTORopathies, and several natural history studies of genetic disorders in partnership with family groups and foundations.

Dr. Prada joined the faculty at Cincinnati Children’s Hospital Medical Center in 2013. He became director of the RASopathies Program in 2016 and director of the Neurofibromatosis Program in 2020 at Cincinnati Children’s Hospital. In 2021, Dr. Prada joined Lurie Children’s and the Feinberg School of Medicine at Northwestern University as the Division Head of Genetics, Genomics and Metabolism. 

Dr. Romo specializes in the diagnosis and treatment of people with neurofibromatosis, schwannomatosis, and brain tumors. Dr. Romo earned his medical degree from the School of Medicine and Health Sciences at Tecnológico de Monterrey in Mexico and completed his Neurology residency at the University of Arkansas for Medical Sciences, where he served as chief resident. He then completed a Neuro-oncology clinical and research fellowship in a joint program between The Johns Hopkins University and the National Institutes of Health. Dr. Romo additionally trained as a clinical pharmacology fellow at The Johns Hopkins University and completed training on clinical cancer research at the University of Texas MD Anderson Cancer Center. In his research, Dr. Romo studies the natural history and treatments for people with neurofibromatosis. He also studies drug pharmacokinetics and the blood-brain barrier, and investigates better ways to reach tumors in the central nervous system. In addition to patient care and research, Dr. Romo teaches and mentors medical and undergraduate students to help develop a future generation of neurologists.

Konstantina “Tina” Stankovic, MD, PhD, FACS is the Bertarelli Foundation Professor and Chair of the Department of Otolaryngology – Head & Neck Surgery at Stanford University School of Medicine. She is a Harvard-trained ear and skull-base surgeon and a Massachusetts Institute of Technology-trained auditory neuroscientist. Her clinical focus is in otology and neurotology, and she previously served as Chief of the Division of Otology and Neurotology at Massachusetts Eye and Ear, a teaching hospital of Harvard Medical School. In addition to her clinical and administrative duties, she directs a basic science laboratory focused on improving diagnostics and therapeutics for sensorineural hearing loss. She has initiated and led successful cross departmental, national, and international collaborations to develop and deploy novel molecular diagnostics and therapeutics for hearing loss and otologic diseases in general while educating the next generation of leaders in surgery and science.